Results 51 to 60 of about 76,403 (315)

Long Noncoding RNA LUCAT1 Promotes Multiple Myeloma Cell Growth by Regulating the TGF-β Signaling Pathway

Technology in Cancer Research & Treatment, 2020
Objective: Long noncoding RNAs (lncRNAs) are potential biomarkers for cancers. Nevertheless, the ability of long noncoding RNA lung cancer-associated transcript 1 in patients with multiple myeloma remains unknown. The purpose of this current study was to
Zhaoyu Liu MM, Hong Gao MD, Qing Peng MM, Yongheng Yang MM   +3 more
doaj   +1 more source

Biomaterial Strategies for Targeted Intracellular Delivery to Phagocytes

Advanced Functional Materials, EarlyView.
Phagocytes are essential to a functional immune system, and their behavior defines disease outcomes. Engineered particles offer a strategic opportunity to target phagocytes, harnessing inflammatory modulation in disease. By tuning features like size, shape, and surface, these systems can modulate immune responses and improve targeted treatment for a ...
Kaitlyn E. Woodworth, Neal I. Callaghan, Locke Davenport Huyer   +2 more
wiley   +1 more source

Self‐Assembling Multi‐Antigen T Cell Hybridizers for Precision Immunotherapy of Multiple Myeloma

Advanced Healthcare Materials, EarlyView.
A novel modular T‐cell engager platform, MATCH, is developed for personalized multiple myeloma therapy. MATCH uses complementary oligonucleotide‐linked Fab’ fragments to enable flexible targeting of MM antigens and controlled T‐cell activation. The system shows potent, antigen‐specific cytotoxicity in vitro and in vivo, highlighting its potential for ...
Shannuo Li, Jiahui Li, Hasan Al Faruque, Paul Shami, Birgit Knoechel, Jens Lohr, Douglas Sborov, Jiyuan Yang, Jindřich Kopeček   +8 more
wiley   +1 more source

In Silico Approach for Identification of PI3K/mTOR Dual Inhibitors for Multiple Myeloma Treatment

European Journal of Biology, 2023
Objective: Multiple myeloma is a hematologic malignancy in which targeting phosphoinositide 3 kinase (PI3K) and/or the mammalian target of rapamycin (mTOR) individually has been shown to have anti-proliferative effects, however, inhibiting both proteins ...
İlke Maşalacı, Yaren Akdoğan, Özge Mutlu, Hande Eyvaz, Yağmur Kiraz   +4 more
doaj   +1 more source

Label‐Free FET Based Biosensor for Detection of Engineered CAR T‐Cells at Single Cell Resolution

Advanced Sensor Research, EarlyView.
A silicon nanowire field‐effect transistor (SiNW FET) biosensor that allows for label‐free, real‐time detection and quantification of engineered Chimeric Antigen Receptor (CAR) T‐cells at single‐cell resolution is presented. By mimicking the CAR‐specific antigen interface, the platform provides highly selective analysis of individual cell surface ...
Trang Anh Nguyen‐Le, Isli Cela, Anja Feldmann, Chang‐Ki Baek, Michael Bachmann, Larysa Baraban   +5 more
wiley   +1 more source

Genetic Engineering Methods in Primary T Cells

Advanced Therapeutics, EarlyView.
Primary T cells can be engineered to confer them with novel therapeutic functions, allowing them to treat a variety of conditions. Genetic engineering can be either stable or transient, aiming to either express or inhibit a target gene. This review discusses the various genetic engineering tools available as well as their characteristics and ...
Anthony Youssef, Hui‐Shan Li
wiley   +1 more source

Calcium Channel Blocker Verapamil Enhances Reticulum Stress and Death Induced by Proteasome Inhibition in Myeloma Cells

Neoplasia: An International Journal for Oncology Research, 2010
The proteasome inhibitor bortezomib is clinically approved for the treatment of multiple myeloma. However, long-term remissions are difficult to achieve, and myeloma cells often develop secondary resistance to proteasome inhibitors.
Silke Meister, Benjamin Frey, Veronika R. Lang, Udo S. Gaipl, Georg Schett, Ursula Schlötzer-Schrehardt, Reinhard E. Voll   +6 more
doaj   +1 more source

Epigenetic Activation of CCDC183‐AS1 Promotes Osteoclastogenesis and Prostate Cancer Bone Metastasis Through the FUBP1/LIGHT Axis

Advanced Science, EarlyView.
CCDC183‐AS1 overexpression enhanced the ability of PCa cells to spread to the bone by inducing osteoclastogenesis. Mechanistically, CCDC183‐AS1 interacted with FUBP1 and enhanced its stability, which promoted the transcription of TNFSF14 (LIGHT). Copy number gain‐induced KDM5C epigenetically upregulated CCDC183‐AS1 expression by recruiting TET1 to the ...
Chuandong Lang, Xiangyu Mu, Kun Chen, Xinwen Wang, Yuluo Rong, Jia Wang, Zongcheng Yang, Chi Yin, Yuhu Dai, Jun Xiao, Wenzhi Zhang   +10 more
wiley   +1 more source

TNF receptor–related factor 3 inactivation promotes the development of intrahepatic cholangiocarcinoma through NF‐κB‐inducing kinase–mediated hepatocyte transdifferentiation

Hepatology, EarlyView., 2022
Abstract Background and Aims Intrahepatic cholangiocarcinoma (ICC) is a deadly but poorly understood disease, and its treatment options are very limited. The aim of this study was to identify the molecular drivers of ICC and search for therapeutic targets.
Yuto Shiode, Takahiro Kodama, Satoshi Shigeno, Kazuhiro Murai, Satoshi Tanaka, Justin Y. Newberg, Jumpei Kondo, Shogo Kobayashi, Ryoko Yamada, Hayato Hikita, Ryotaro Sakamori, Hiroshi Suemizu, Tomohide Tatsumi, Hidetoshi Eguchi, Nancy A. Jenkins, Neal G. Copeland, Tetsuo Takehara   +16 more
wiley   +1 more source

PTPN2 Inhibition Disrupts Mitochondrial Renewal and Blocks TFRC‐Mediated Mitophagy to Exert Anti‐Tumor Activities in ALK‐Positive Anaplastic Large Cell Lymphoma

Advanced Science, EarlyView.
CRISPR/Cas9 screening reveals PTPN2 as essential for ALK+ ALCL survival. PTPN2 regulates TFRC to promote PINK1‐PRKN mitophagy. Oral PTPN2 inhibitor ABBV‐CLS‐484 disrupts mitochondrial renewal and blocks TFRC‐mediated mitophagy to exert anti‐tumor activities, supporting clinical development for ALK+ ALCL.
Wei‐Ting Wang, Zi‐Wen Duan, Tong‐Yao Xing, Wei Hua, Kai‐Xing Du, Chun‐Yu Shang, Yi‐Fan Wu, Li Wang, Jian‐Yong Li, Rui Gao, Jin‐Hua Liang, Wei Xu   +11 more
wiley   +1 more source